Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Tomas-Navarro, Jose, Hernandez-Rivas, Jose Angel, Ribera, Josep Maria, Sancho, Juan Manuel, Oriol, Albert, Pujol, Misericordia, Milla, Fuensanta, Feliu, Evarist
Materyal Türü: Recurso digital
Dil:İngilizce
Baskı/Yayın Bilgisi: Zenodo 1998
Konular:
Online Erişim:https://doi.org/10.5281/zenodo.14743016
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
İçindekiler:
  • <p><strong>Background and objective: </strong>The threshold for prophylactic platelet transfusions has been classically established at 20,000/microL. In 48 patients with de novo acute myeloblastic leukemia (AML) we analyzed the effect of reducing the threshold for prophylactic platelet transfusion from 20,000/microL (group A) to 10,000/microL (group B) after induction and consolidation chemotherapy.</p> <p><strong>Design and methods: </strong>Forty-eight adult patients with de novo AML diagnosed in a single institution in a nine year period were enrolled in the study. Between January 1989 and December 1993 the patients received prophylactic platelet transfusions when their platelet count was below 20,000/microL (group A), and from January 1994 to March 1998 prophylactic platelet transfusions were indicated below 10,000/microL or between 10,000/microL and 20,000/microL if there was any consumption factor.</p> <p><strong>Results: </strong>The mean number (SD) of platelet transfusions during induction was 8.4 (5.3) in group A and 8.5 (5.5) in group B; and during consolidation 4.7 (3.4) in group A and 4.6 (3.8) in group B (p = n.s.). Excluding the cases with consumption factors from the analysis, group B patients required 34% fewer transfusions during induction and 15.5% fewer during consolidation (p = 0.04). There were no differences between groups regarding major bleeding episodes.</p> <p><strong>Interpretation and conclusions: </strong>Our data show that the threshold for prophylactic platelet transfusion can be safely set at 10,000 microL during induction and consolidation chemotherapy for adult patients with de novo AML.</p>